Atea Pharmaceuticals, Inc.

This study tested a new combination of two oral drugs, bemnifosbuvir and ruzasvir, in 275 adults with chronic hepatitis C. The main goal was to see if the treatment could clear the virus from the blood 12 weeks after finishing the medication, which would mean a cure. The approach…

This study looked at how a new drug combination for hepatitis C (bemnifosbuvir/ruzasvir) affects the way birth control pills (ethinyl estradiol/levonorgestrel) are processed in the body. It involved 24 healthy women who were past menopause or surgically sterile. The goal was to c…